Koc I, et al. - A comparative analysis was performed of the visual and anatomical outcomes of intravitreal ranibizumab (group 1), bevacizumab (group 2), and triamcinolone (group 3) for center-involving diabetic macular edema. Similar effects were determined through the three treatment methods, in terms of the improvement in visual acuity (VA). Nonetheless, intravitreal triamcinolone yielded an additional anatomical improvement.